The Week of July 8 in Review
The week of July 8 in review, featuring clinical articles and videos on targeting the PI3K and AKT pathways, ASCO's CancerLinQ program, and ibrutinib in CLL and MCL.
Dr. Carvajal on the Design of a Trial Analyzing Selumetinib in Advanced Uveal Melanoma
Results for Cetuximab Versus Bevacizumab in mCRC
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the design of a phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma.Frontline cetuximab plus FOLFIRI (folinic acid, fluorouracil, and irinotecan) improved overall survival (OS) by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wildtype metastatic colorectal cancer (mCRC), according to results from the German phase III FIRE-3 study.
Targeting the PI3K and AKT Pathways in Solid Tumors
The next-generation PI3 kinase (PI3K) inhibitor GDC-0032 has shown signs of efficacy in patients with advanced cancers that were mutated for the PI3Kalpha gene.
Dr. Hudis Describes ASCO's CancerLinQ Program
Clifford A. Hudis, MD, ASCO President-Elect, Chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, describes the American Society of Clinical Oncology's (ASCO) CancerLinQ program.
HER2 Expression Level Associated With Response to T-DM1 in HER2+ Metastatic Breast Cancer
High levels of HER2 expression in metastatic breast cancer tumors correlated with increased benefit from treatment with adotrastuzumab (T-DM1), according to a subanalysis of data from the phase III EMILIA trial.
Dr. Tewari on the Next Steps for Bevacizumab in Recurrent Cervical Cancer
Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.
New Drug Application Filed for Ibrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
The FDA has received a new drug application for ibrutinib as a therapy for previously treated chronic lymphocytic leukemia (CLL) and previously treated mantle cell lymphoma (MCL). The new drug application comes after high response rates observed in two clinical trials published last month.
Dr. Marcia Brose on Repurposing Drugs to Treat Thyroid Cancer
Marcia Brose, MD, PhD, an assistant professor of otolaryngology and head and neck surgery in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, discusses repurposing drugs to treat thyroid cancer.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
